

CONTENTS

List of Tables	VII
List of Figures	IX
List of Abbreviations	XI
Chapter Title	Page No.
CHAPTER 1: Introduction	
1.1 Research envisaged	8
1.2 References	9
CHAPTER 2: LITERATURE REVIEW	
2.1 HUMAN RESPIRATORY SYSTEM	14
2.1.1 Pulmonary ventilation	15
2.1.2 Major components of the lung - barriers to drug absorption	17
2.1.2.1 Epithelium	17
2.1.2.2 Endothelium	18
2.1.2.3 Alveolar macrophages	18
2.1.2.4 Interstitium and basement membrane	18
2.1.2.5 Lymphatic system	19
2.1.2.6 Epithelial lining fluid	19
2.1.2.7 Surfactant	20
2.1.2.8 Mucociliary clearance	20
2.1.2.9 Patho-physiological changes	21
2.1.2.10 Particle deposition	21
2.1.3 Inhaler devices	22
2.1.3.1 Nebulizers	22
2.1.3.2 Pressurized metered dose inhalers	24
2.1.3.3 Dry powder inhalers	24
2.1.4 Factors influencing DPI formulation design	25
2.1.4.1 Physical properties of powders	25
2.1.4.2 Drug carrier	27
2.1.4.3 Particle engineering	28
2.1.4.4 Metering design	29
2.1.4.5 Flow path design	31
2.1.5 Regulatory and pharmacopoeial requirements	32
2.2 TUBERCULOSIS	35
2.2.1 Etiologic agent	35
2.2.2 Epidemiology	35
2.2.3 Exposure to infection	36
2.2.4 Infection to disease	36
2.2.5 Strategies for Tuberculosis Control	36
2.2.6 Detection and treatment of infectious cases	37
2.2.7 Treatment failure and relapse	38
2.2.8 Dual Crises: Tuberculosis and HIV	38
2.2.9 Diversity	39
2.3 LIPOSOMES	40
2.3.1 Composition of liposomes	40
2.3.1.1 Phospholipids	40
2.3.1.2 Sterols	40
2.3.1.3 Antioxidant	42

2.3.1.4	Other non-structural components	42
2.3.2	Types of liposomes	42
2.3.3	Methods of preparation of liposomes	43
2.3.4	Characterization of liposomes	43
2.3.4.1	Size and size distribution	43
2.3.4.2	Lamellarity	43
2.3.4.3	Entrapped/Internal volume	43
2.3.4.4	Determination of percentage capture	43
2.3.4.5	Chemical analysis	44
2.3.5	Stability of liposomes	44
2.3.6	Liposomes as drug delivery systems	47
2.4	LIPOSOMES AS PULMONARY DRUG DELIVERY SYSTEM	49
2.4.1	Constraints of pulmonary drug delivery	51
2.4.2	Controlled drug delivery to the lung	52
2.4.3	Pharmacokinetic and pharmacological studies	53
2.4.4	Development of a liposomal dosage form	56
2.4.4.1	Delivery as an aerosol	56
2.4.4.2	Pharmaceutical considerations	58
2.5	DEVELOPMENT OF DRY POWDER INHALATION FORMULATION	59
2.6	DRUG PROFILES	62
2.6.1	Isoniazid	62
2.6.1.1	Physical properties	62
2.6.1.2	Pharmacology	62
2.6.1.1	Pharmacokinetics	62
2.6.1.3	Therapeutic use	63
2.6.1.4	Adverse reaction	63
2.6.1.5	Methods for estimation	64
2.6.2	Rifampicin	65
2.6.2.1	Physical properties	65
2.6.2.2	Pharmacology	65
2.6.2.1	Pharmacokinetics	65
2.6.2.3	Therapeutic use	66
2.6.2.4	Adverse reaction	66
2.6.2.5	Methods for estimation	67
2.7	REFERENCES	68
CHAPTER 3: ANALYTICAL METHODS		
3.1	INTRODUCTION	84
3.2	MATERIALS AND EQUIPMENTS	84
3.3	PHYSICAL ANALYSIS OF LIPOSOMES	85
3.3.1	Determination of shape and lamellarity of liposomes	85
3.3.2	Determination of particle size of liposomes	85
3.4	CHEMICAL ANALYSIS	86
3.4.1	Estimation of Phosphatidyl Choline	86
3.4.1.1	Solutions	86
3.4.1.2	Procedure for calibration curve	86
3.4.1.3	Stability and selectivity	87
3.4.1.4	Estimation of phosphatidyl choline from liposomes/ supernatant	87
3.4.2	Estimation of cholesterol	88

3.4.2.1	Solutions	88
3.4.2.2	Procedure for calibration curve	88
3.4.2.3	Stability and selectivity	89
3.4.2.4	Estimation of cholesterol from liposomes/ supernatant	89
3.4.3	Estimation of Isoniazid	90
3.4.3.1	Solutions	90
3.4.3.2	Procedure for calibration curve	90
3.4.3.3	Stability and selectivity	91
3.4.3.4	Estimation of Isoniazid from liposomes/ supernatant	91
3.4.3.5	Estimation of INH from LDPI formulations	91
3.4.3.6	Estimation of INH retention and vesicle size determination in liposomal DPI formulations during stability studies	92
3.4.3.7	Estimation of INH in dispersion medium	92
3.4.3.8	Estimation of INH in in-vitro deposition and in- vivo biological fluid and tissues	93
3.4.4	Estimation of Rifampicin	94
3.4.4.1	Solutions	94
3.4.4.2	Procedure for calibration curve	94
3.4.4.3	Stability and selectivity	94
3.4.4.4	Estimation of Rifampicin from liposomes/ supernatant	94
3.4.4.5	Estimation of RFP from LDPI formulations	95
3.4.4.6	Estimation of RFP retention and vesicle size determination in liposomal DPI formulations during stability studies	95
3.4.4.7	Estimation of RFP in dispersion medium	96
3.4.4.8	Estimation of RFP in in-vitro deposition and in- vivo biological fluid and tissues	96
3.4.5	Estimation of water content and trapped volume	97
3.5	RESULTS AND DISCUSSION	98
3.5.1	Estimation of phosphatidyl choline	98
3.5.2	Estimation of cholesterol	99
3.5.3	Estimation of Isoniazid	100
3.5.4	Estimation of Rifampicin	101
3.6	REFERENCES	102
CHAPTER 4: PREPARATION AND CHARACTERIZATION OF LIPOSOMES		
4.1	INTRODUCTION	104
4.2	MATERIALS AND EQUIPMENTS	106
4.3	PREPARATION OF INH LIPOSOMES BY TFH	106
4.4	PREPARATION OF INH LIPOSOMES BY REV	107
4.5	DRUG LOADING	107
4.6	PREPARATION OF RFP LIPOSOMES BY TFH	111
4.7	PREPARATION OF RFP LIPOSOMES BY REV	111
4.8	PARTICLE SIZE REDUCTION AND SEPARATION OF UNENTRAPPED DRUG	115
4.9	LIPOSOME CHARACTERIZATION	115

4.9.1	Trapped volume	115
4.9.2	Liposome size	116
4.9.3	Shape and lamellarity	116
4.9.4	Percent drug entrapment	116
4.10	STATISTICAL ANALYSIS	117
4.11	RESULTS AND DISCUSSION	117
4.11.1	Optimization of TFH and REV methods process variables	117
4.11.2	Optimization of THF and REV methods formulation variables	121
4.11.3	Drug (INH) loading	124
4.11.3.1	Preparation of INH-Ethylene Diamine Tetra Acetic acid complex	124
4.11.3.2	Optimization of transmembrane loading of INH in to liposomes	124
4.11.4	Selection of method for liposome size reduction and separation of untrapped drug	130
4.11.4.1	Liposomal particle size reduction method	130
4.11.4.2	Selection of method for separation of untrapped drug	130
4.11.5	Characterization of liposomes	131
4.11.5.1	Trapped volume	131
4.11.5.2	Liposomal size	134
4.11.5.3	Photomicrography	134
4.11.5.4	Percent drug entrapment	134
4.12	REFERENCES	135
CHAPTER 5: PREPARATION AND CHARACTERIZATION OF LIPOSOMAL DRY POWDER INHALER		
5.1	INTRODUCTION	138
5.2	LYOPHILIZATION OF LIPOSOMES	141
5.2.1	INH liposomes	141
5.2.2	RFP liposomes	144
5.3	METHOD OF PREPARATION OF LIPOSOMAL DRY POWDER INHALER FORMULATIONS	144
5.3.1	INH LDPI formulation	145
5.3.1.1	Effect of carrier mass ratio	145
5.3.1.2	Effect of adding fines	145
5.3.1.3	Effect of adding sequence of fine	145
5.3.2	RFP LDPI formulation	146
5.3.2.1	Effect of carrier mass ratio	146
5.3.2.2	Effect of adding fines	146
5.3.2.3	Effect of adding sequence of fine	146
5.4	LDPI FORMULATION CHARACTERIZATION	149
5.4.1	Angle of repose	149
5.4.2	Compressibility index	149
5.4.3	Particle size determination	149
5.4.3.1	Rehydrated liposomal particle size determination	149
5.4.3.2	Liposomal Dry Powder particle size determination	149
5.4.3.3	Mass Median Aerodynamic particle size determination	150
5.4.4	Photomicrography	150

5.4.5	SEM photomicrographs	150
5.4.6	Fine particle fraction	151
5.4.7	Residual water content and moisture sorption determination	152
5.4.8	Percent drug retained	152
5.5	STATISTICAL ANALYSIS	152
5.6	RESULTS AND DISCUSSION	153
5.6.1	Optimization of lyophilization of liposomes	153
5.6.1.1	Selection of cryoprotectant	153
5.6.1.2	Phase of cryoprotectant addition	154
5.6.1.3	Mass ratio of lipid: sucrose	155
5.6.2	Optimization of LDPI formulation	156
5.6.2.1	Effect of carrier particle ratio	156
5.6.2.2	Effect of fine particle addition and addition sequence	157
5.6.3	Characterization of LDPI formulations	158
5.6.3.1	Angle of repose and compressibility index	158
5.6.3.2	Particle size characterization	158
5.6.3.3	Photomicrography and SEM photomicrographs	162
5.6.3.4	Fine particle fraction	165
5.6.3.5	Residual water content and moisture sorption determination	167
5.6.4	Percent drug retained	167
5.7	REFERENCES	170
CHAPTER 6: STABILITY TESTING OF LIPOSOMAL DRY POWDER INHALER FORMULATIONS		
6.1	INTRODUCTION	176
6.2	METHOD	176
6.3	STATISTICAL ANALYSIS	177
6.4	RESULTS AND DISCUSSION	182
5.4.1	Stability of INH LDPI formulations	182
5.4.2	Stability of RFP LDPI formulations	183
6.5	REFERENCES	189
CHAPTER 7: IN VITRO DIFFUSION STUDIES		
7.1	INTRODUCTION	191
7.2	DRUG DIFFUSION STUDIES ACROSS ARTIFICIAL MEMBRANE	192
7.2.1	Experimental setup	192
7.2.1.1	Artificial membrane	192
7.2.1.2	Design of diffusion cell	192
7.2.1.3	Validation of diffusion cell	192
7.2.1.4	Selection of diffusion medium	193
7.2.2	Method	193
7.3	IN VITRO ALVEOLAR MACROPHAGES UPTAKE STUDIES	193
7.3.1	Method	193
7.4	DATA AND STATISTICAL ANALYSIS	194
7.5	RESULTS AND DISCUSSION	195
7.6	REFERENCES	201
CHAPTER 8: IN VIVO STUDIES		
8.1	INTRODUCTION	203

8.2	INTRATRACHEAL INSTILLATION	203
8.3	BIOLOGICAL SAMPLING	204
8.4	TOXICITY STUDIES	205
8.5	DATA AND STATISTICAL ANALYSIS	205
8.6	RESULTS AND DISCUSSION	206
8.7	REFERENCES	213
CHAPTER 9: Summary and conclusion		
9.1	Summary	215
9.2	Conclusion	225
Research Publications		